Metro . The key comments by bioshares are as follows.
1.The fda approval for axiron represents an outstanding achievement for the australian biotech industry.
2.The market opportunity for axiron is significant from several points of view.
3.Dividend could be announced at tomorrow agm.Bioshares believe the company could comfortably return 50 cents per share tax free.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $19.90K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 463664 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 320000 | 2 |
View Market Depth
| Last trade - 15.56pm 25/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |